Literature DB >> 15557632

A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential.

Robert H Copenhaver1, Eliud Sepulveda, Lisa Y Armitige, Jeffrey K Actor, Audrey Wanger, Steven J Norris, Robert L Hunter, Chinnaswamy Jagannath.   

Abstract

The fbpA and fbpB genes encoding the 85A and 85B proteins of Mycobacterium tuberculosis H37Rv, respectively, were disrupted, the mutants were examined for their ability to survive, and the strain lacking 85A (DeltafbpA) was tested for its ability to immunize mice. The DeltafbpA mutant was attenuated in mice after intravenous or aerosol infection, while replication of the DeltafbpB mutant was similar to that of the wild type. Complementation of the fbpA gene in DeltafbpA restored its ability to grow in the lungs of mice. The DeltafbpA mutant induced a stronger expression of pulmonary mRNA messages in mice for tumor necrosis factor alpha, interleukin-1 beta (IL-1beta), gamma interferon, IL-6, IL-2, and inducible nitric oxide (NO) synthase, which led to its decline, while H37Rv persisted despite strong immune responses. H37Rv and DeltafbpA both induced NO in macrophages and were equally susceptible to NO donors, although DeltafbpA was more susceptible in vitro to peroxynitrite and its growth was enhanced by NO inhibitors in mice and macrophages. Aerosol-infected mice, which cleared a low-dose DeltafbpA infection, resisted a challenge with virulent M. tuberculosis. Mice subcutaneously immunized with DeltafbpA or Mycobacterium bovis BCG and challenged with M. tuberculosis also showed similar levels of protection, marked by a reduction in the growth of challenged M. tuberculosis. The DeltafbpA mutant was thus attenuated, unlike DeltafbpB, but was also vaccinogenic against tuberculosis. Attenuation was incomplete, however, since DeltafbpA revived in normal mice after 370 days, suggesting that revival was due to immunosenescence but not compensation by the fbpB or fbpC gene. Antigen 85A thus affects susceptibility to peroxynitrite in M. tuberculosis and appears to be necessary for its optimal growth in mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557632      PMCID: PMC529100          DOI: 10.1128/IAI.72.12.7084-7095.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages.

Authors:  L Y Armitige; C Jagannath; A R Wanger; S J Norris
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis.

Authors:  J T Belisle; V D Vissa; T Sievert; K Takayama; P J Brennan; G S Besra
Journal:  Science       Date:  1997-05-30       Impact factor: 47.728

3.  A role for complement C5 in organism containment and granulomatous response during murine tuberculosis.

Authors:  J K Actor; E Breij; R A Wetsel; H Hoffmann; R L Hunter; C Jagannath
Journal:  Scand J Immunol       Date:  2001-05       Impact factor: 3.487

4.  Silencing of oxidative stress response in Mycobacterium tuberculosis: expression patterns of ahpC in virulent and avirulent strains and effect of ahpC inactivation.

Authors:  B Springer; S Master; P Sander; T Zahrt; M McFalone; J Song; K G Papavinasasundaram; M J Colston; E Boettger; V Deretic
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  A mouse model of the recrudescence of latent tuberculosis in the elderly.

Authors:  I M Orme
Journal:  Am Rev Respir Dis       Date:  1988-03

6.  "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms.

Authors:  L K Keefer; R W Nims; K M Davies; D A Wink
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

7.  Deletion of the putative antioxidant noxR1 does not alter the virulence of Mycobacterium tuberculosis H37Rv.

Authors:  G R Stewart; S Ehrt; L W Riley; J W Dale; J McFadden
Journal:  Tuber Lung Dis       Date:  2000

8.  Vaccinated mice remain more susceptible to Mycobacterium tuberculosis infection initiated via the respiratory route than via the intravenous route.

Authors:  R J North; R LaCourse; L Ryan
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

9.  Naive human T cells develop into Th1 effectors after stimulation with Mycobacterium tuberculosis-infected macrophages or recombinant Ag85 proteins.

Authors:  D M Russo; N Kozlova; D L Lakey; D Kernodle
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

10.  Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH.

Authors:  Deepak Kaushal; Benjamin G Schroeder; Sandeep Tyagi; Tetsuyuki Yoshimatsu; Cherise Scott; Chiew Ko; Liane Carpenter; Jyoti Mehrotra; Yukari C Manabe; Robert D Fleischmann; William R Bishai
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

View more
  23 in total

1.  Evaluation of a temperature-restricted, mucosal tuberculosis vaccine in guinea pigs.

Authors:  Tuhina Gupta; Monica LaGatta; Shelly Helms; Rebecca L Pavlicek; Simon O Owino; Kaori Sakamoto; Tamas Nagy; Stephen B Harvey; Mark Papania; Stephanie Ledden; Kevin T Schultz; Candace McCombs; Frederick D Quinn; Russell K Karls
Journal:  Tuberculosis (Edinb)       Date:  2018-10-19       Impact factor: 3.131

2.  A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.

Authors:  Shen-An Hwang; Katarzyna Wilk; Marian L Kruzel; Jeffrey K Actor
Journal:  Vaccine       Date:  2009-04-05       Impact factor: 3.641

3.  Label-free proteomics and systems biology analysis of mycobacterial phagosomes in dendritic cells and macrophages.

Authors:  Qingbo Li; Christopher R Singh; Shuyi Ma; Nathan D Price; Chinnaswamy Jagannath
Journal:  J Proteome Res       Date:  2011-03-30       Impact factor: 4.466

4.  Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis.

Authors:  Thulasi Warrier; Marielle Tropis; Jim Werngren; Anne Diehl; Martin Gengenbacher; Brigitte Schlegel; Markus Schade; Hartmut Oschkinat; Mamadou Daffe; Sven Hoffner; Ali Nasser Eddine; Stefan H E Kaufmann
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 5.  The ins and outs of Mycobacterium tuberculosis protein export.

Authors:  Lauren S Ligon; Jennifer D Hayden; Miriam Braunstein
Journal:  Tuberculosis (Edinb)       Date:  2011-12-21       Impact factor: 3.131

6.  The ΔfbpA attenuated candidate vaccine from Mycobacterium tuberculosis, H37Rv primes for a stronger T-bet dependent Th1 immunity in mice.

Authors:  Cherie M Roche; Amanda Smith; Devin R Lindsey; Akshay Meher; Kimberly Schluns; Ashish Arora; Lisa Y Armitige; Chinnaswamy Jagannath
Journal:  Tuberculosis (Edinb)       Date:  2011-11-13       Impact factor: 3.131

7.  Mycobacterial Trehalose 6,6'-Dimycolate-Induced M1-Type Inflammation.

Authors:  Thao K T Nguyen; John d'Aigle; Luis Chinea; Zainab Niaz; Robert L Hunter; Shen-An Hwang; Jeffrey K Actor
Journal:  Am J Pathol       Date:  2019-11-14       Impact factor: 4.307

Review 8.  TB research at UT-Houston--a review of cord factor: new approaches to drugs, vaccines and the pathogenesis of tuberculosis.

Authors:  Robert L Hunter; Lisa Armitige; Chinnaswamy Jagannath; Jeffrey K Actor
Journal:  Tuberculosis (Edinb)       Date:  2009-12       Impact factor: 3.131

9.  Protein dynamics in iron-starved Mycobacterium tuberculosis revealed by turnover and abundance measurement using hybrid-linear ion trap-Fourier transform mass spectrometry.

Authors:  Prahlad K Rao; G Marcela Rodriguez; Issar Smith; Qingbo Li
Journal:  Anal Chem       Date:  2008-08-09       Impact factor: 6.986

Review 10.  Current efforts and future prospects in the development of live mycobacteria as vaccines.

Authors:  Tony W Ng; Noemí A Saavedra-Ávila; Steven C Kennedy; Leandro J Carreño; Steven A Porcelli
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.